Trials / Completed
CompletedNCT01762293
A Study of Famitinib in Patients With Advanced Colorectal Cancer
A Randomized, Placebo-controlled, Double-blind, Multicenter, Phase IIb Study of Famitinib as Third Line Treatment in Patients With Advanced Colorectal Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 154 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3, and it's anti-angiogenesis effect has been viewed in preclinical tests. Phase I study has shown that the toxicity is manageable. The purpose of this study is to determine whether Famitinib can improve progression free survival compared with placebo in patients with advanced colorectal cancer who failed in previous at least two lines of chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Famitinib | Famitinib 25 mg p.o. qd |
| OTHER | placebo | p.o. qd |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2014-09-01
- Completion
- 2014-10-01
- First posted
- 2013-01-07
- Last updated
- 2018-04-18
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01762293. Inclusion in this directory is not an endorsement.